{
    "id": "47190845",
    "text": "Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525. Ieramilimab's first clinical trial is a Phase I in expected to be in patients with various solid tumors, in combination with PDR001, an anti-PD-1 monoclonal antibody. (ClinicalTrials.gov identifier NCT02460224). ==References== Category:Experimental cancer drugs Category:Monoclonal antibodies ",
    "title": "Ieramilimab"
}